



Media
Sponsors:



A VerticalSM company



Supporting
Organisations:



S•E•C•A
Swiss Private Equity
& Corporate
Finance Association

SACHS
ASSOCIATES

Bloomberg

EUROPEAN BIOTECH INVESTMENT FORUM

For start-ups, venture-funded and small cap companies

6 & 7 November 2001 • Arabella Sheraton Grand Hotel, Munich

Main Sponsor:

Bank Vontobel

Co-Sponsors:

Baker & McKenzie • DVC Deutsche Venture Capital

Katan Associates • Kirchhoff Consult AG

Novartis Venture Fund • SWX Swiss Exchange

With the support of:

FINANCIAL TIMES
DEUTSCHLAND

For latest update visit: www.sachsforum.com

6 November 2001 – DAY ONE

8.50 **CHAIRMAN'S OPENING REMARKS**
Prof. Dr. Horst Domdey, CEO, **Bio-M AG**

9.00 **BIOETHICS AND POLITICAL DEVELOPMENTS IN EUROPE**
Dr. Eric Tambuyzer
Chairman EuropaBio Board of Management,
Vice President, Corporate Affairs Europe,
GENZYME Corporation

9.20 **OVERVIEW OF THE IPO & PRIVATE PLACEMENT MARKET**
Barbara Heller, First Vice President
Claudio Werder, First Vice President,
Head of Life Sciences Team
Bank Vontobel AG

9.40 **EUROPEAN BIOTECH AND IPO**
Robert Wyss, Head SWX New Market
SWX Swiss Exchange

10.00 **VALUE CONSIDERATIONS IN EARLY STAGE BIOTECH VENTURES**
Dr. Rudolf Gygax, Portfolio and Business Manager
Novartis Venture Fund

10.20 **THE EVOLVING GERMAN BIOTECH LANDSCAPE**
Dr. Jörg Neermann, Senior Partner
DVC Deutsche Venture Capital

10.40 **BAKER & MCKENZIE**
– *Tbc*

10.55 *Break*

11.15 **SECTOR PANEL**
LIFE SCIENCE INVESTMENT OPPORTUNITIES
Chair: Dr. Juerg Meier
Novartis Venture Fund
Dr. Alexandra Goll, Partner
TVM Techno Venture Management
– *Models and Reality Check*

Prof. Dr. Kai Deusch, Director
Apax Partners
– *Is Biotech a B2B Marketplace?*
Kate Bingham, General Partner
Schroder Ventures Life Sciences
– *Venture Financing*
Dr. Holger N. Mueller, Investment Director
3i Deutschland
– *Capturing the value of knowledge generated in biotech companies*

12.30 **ACADEMIC KEYNOTE**
Professor Stephen K. Smith
Head of Department, Obstetrics & Gynaecology
University of Cambridge
– *Science-based Developments in Women's Health*

12.50 *Lunch*

14.05 **PARTNERING MODELS FOR PHARMACEUTICALS AND BIOTECHNOLOGY COMPANIES**
GlaxoSmithKline
– *Tbc*

14.25 **VENTURE FINANCE PANEL**
Chair: Dr. Hans A Küpper, Managing Director
Life Sciences Ventures GmbH
– *Growth Strategies & Business Models*
Robert Zegelaar, Principal
Atlas Venture
Nick Lowcock,
Managing Director, European Healthcare,
E.M. Warburg, Pincus & Co. International, Ltd.
Philip Rattle, Director
JPMorgan Partners
Dr. Fredrik Buch, Partner
HealthCap

15.40 **STREAMED COMPANY PRESENTATION WORKSHOPS**

15.40 STREAMED COMPANY PRESENTATION WORKSHOPS FEATURING UP TO 30 START-UP – PRE-IPO COMPANIES

Post-Genomics: PharmacoGenomics & Proteomics	Immunology / Oncology	Therapeutics
Tea/Coffee		
Medical Devices, Diagnostics	Biomedical Engineering and Bio Materials	Bioinformatics, SNP, Array Technology

6.30 Cocktail Party – Atlanta Foyer

7 November 2001 – DAY TWO

8.50	CHAIRMAN Stan Yakatan , Chairman, Katan Associates	Mr. Otello Stampacchia , Vice President of Immunology, Lombard Odier & Cie
9.00	GLOBAL DEVELOPMENT PANEL <i>Germany / Scandinavia / Israel / UK / Switzerland</i> Dr. Jens A. Katzek , Managing Director, German Association of Biotechnology Industries (DIB) Dr. Jeff Solomon , Chief Executive, ERBI, UK Prof. Dr. Jesper Zeuthen , Managing Director, BankInvest Bio Venture	Dr. Dalia Megiddo , MBA, Managing Partner of Innomed Ventures, Jerusalem Global Ventures – Innomed
		10.15 <i>Break</i>
		10.35 STREAMED COMPANY PRESENTATION WORKSHOPS <i>Continued</i> Featuring up to 24 Start-Up – Pre-IPO Companies
		13.30-15.30 Conclusion of Conference and Networking Lunch

DAY ONE 11.15-12.50

LISTED AND PRE-IPO COMPANY
PRESENTATIONS BREAK-OUT SESSION

SACHS
ASSOCIATES

Bloomberg

Next Meeting:

The 2nd Annual European Venture Capital Forum for Emerging Growth Companies

Leading international venture forum.
The 2001 event featured over 60 presenting
companies and 800 delegates.

January 29-30, 2002

Arabella Sheraton Grand Hotel, Munich

For a further update on this, and
future events, please visit our
website www.sachsforum.com

MAIN SPONSOR



CO-SPONSORS

BAKER & MCKENZIE

Deutsche Venture Capital



PRESENTING OPPORTUNITIES

Should you wish to PRESENT your company
in a sector workshop please contact
alexandra@sachsforum.com

EXHIBITION OPPORTUNITIES

Should you wish to EXHIBIT at the European
Biotech Investment Forum please contact
pernilla@sachsforum.com

PRESENTING COMPANIES INCLUDE:

Applied Spectral Imaging, Ltd
AREVIA GmbH
ARPIDA Ltd
Astex Technology Ltd
atugen AG
BioWisdom Ltd
CNSystems
Medizintechnik GmbH
Contral Pharma Ltd
Cyclacel Limited
ESBATech AG
Frimorfo Ltd
Gene-IT SA
GenOdyssee S.A.
GlycArt Biotechnology Ltd
Graffinity Pharmaceutical
Design GmbH
IDgene Pharmaceuticals Ltd
Igeneon AG
Lorantis Limited
Mologen Holding AG
MTM Laboratories AG
QuantomiX Ltd
R.E.D. Laboratories NV
RiboTargets Ltd
SEDAC –Therapeutics S.A
Speedel Holding AG
The Genetics Company, Inc.
YM BioSciences Inc.
Venture Valuation

